Head-to-head evidence
Alimatravir vs Azvudine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Alimatravir
Developed by Merck & Co.
NCT06045507 · Phase 2 · completed
The study randomized 352 participants to three MK-8527 dose groups or matched placebo and used double blinding, but Alimatravir was not studied and was not the comparator. Its primary endpoints were safety outcomes rather than efficacy, and the registry provides counts without statistical comparisons, so whether the primary comparisons were met cannot be determined.
Next expected readout: January 2027 · NCT07600775 (registry estimate)
Azvudine · FNC
Marketed by Henan Genuine Biotech
NCT04303598 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial testing whether azvudine achieves viral suppression as well as an established comparator, using a recognized clinical measure of HIV control, but results are not yet posted so the outcome is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alimatravir's landscape · Azvudine's landscape